Shares of Illumina, PacBio, Myriad Rise Sharply in January | GenomeWeb

This article has been corrected to fix erroneous information regarding Qiagen. The firm's Q4 revenues increased 5 percent, not decreased 5 percent, as the previous version of the article stated. Also, Qiagen didn't sign a recent companion diagnostic alliance with Amgen.

NEW YORK (GenomeWeb News) – Illumina, Pacific Biosciences, and Myriad Genetics led a group of companies which saw their stocks increase more than 20 percent in January from December as the GenomeWeb Daily News Index rose nearly 7 percent month over month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.